Analysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) Price Target at $46.08
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has received an average rating of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target […]
More Stories
Pentair plc (NYSE:PNR) Shares Bought by Swedbank AB
Swedbank AB grew its stake in shares of Pentair plc (NYSE:PNR – Free Report) by 17.9% in the third quarter,...
iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ) Stock Position Trimmed by Wescott Financial Advisory Group LLC
Wescott Financial Advisory Group LLC cut its position in iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ – Free Report) by...
The PMI Group (OTCMKTS:PPMIQ) and NMI (NASDAQ:NMIH) Head to Head Comparison
NMI (NASDAQ:NMIH – Get Free Report) and The PMI Group (OTCMKTS:PPMIQ – Get Free Report) are both finance companies, but...
Penserra Capital Management LLC Boosts Stake in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY)
Penserra Capital Management LLC lifted its position in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY – Free Report) by...
Pfizer (NYSE:PFE) Stock Acquired Rep. Laurel M. Lee
Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the...
Wescott Financial Advisory Group LLC Trims Stock Holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)
Wescott Financial Advisory Group LLC decreased its holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA – Free Report) by 1.2%...